Valuation: GC Corp.

Market Cap 47TCr 30Cr 26Cr 24Cr 23Cr 43Cr 2.85TCr 44Cr 292.55Cr 113.58Cr 1.41TCr 113.4Cr 110.87Cr 4.91TCr P/E 2024
33.4x
P/E 2025 -10.4x
Enterprise Value 1,86100Cr 120.2Cr 105.21Cr 97Cr 91Cr 170.7Cr 11TCr 173.75Cr 1.16TCr 452.28Cr 5.61TCr 451.6Cr 441.51Cr 20TCr EV / Sales 2024
0.83x
EV / Sales 2025 0.86x
Free-Float
44.46%
Yield 2024
2.89%
Yield 2025 -
11/06 GC Corp.(KOSE:A005250) dropped from KOSPI 200 Index CI
27/05 Green Cross Holdings to divest 460 billion won worth of stake in Curevo RE
15/05 GC Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
31/03 Green Cross Holdings Corporation acquired 22.08% stake in GREEN CROSS WellBeing Corporation from GC Biopharma Corp. for KRW 50.5 billion. CI
18/03 GC Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11/02 Green Cross Holdings Corporation announces Annual dividend, payable on April 17, 2026 CI
14/11 Green Cross Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
14/25/14 Green Cross Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
19/25/19 Green Cross Holdings Corporation agreed to acquire an additional 23.56% stake in GC Care for KRW 71.9 billion. CI
15/25/15 Green Cross Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
18/25/18 Green Cross Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2024 CI
14/24/14 Green Cross Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
06/24/06 China Resources Boya Bio-pharmaceutical Group Co.,Ltd completed the acquisition of 100% stake in Green Cross Hk Holdings Limited from Green Cross Holdings Corporation, Synaptic 1st Private Equity Fund and others for CNY 1.82 billion. CI
1 day-2.94%
1 week-2.38%
Current month-20.67%
1 month-20.67%
3 months-28.12%
6 months-35.29%
Current year-35.62%
1 week 9,490
Extreme 9490
10,690
1 month 9,490
Extreme 9490
12,920
Current year 9,490
Extreme 9490
18,010
1 year 9,490
Extreme 9490
18,010
3 years 9,490
Extreme 9490
18,490
5 years 9,490
Extreme 9490
36,550
10 years 9,490
Extreme 9490
56,300
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2010
Chief Executive Officer 72 25/03/2010
Director of Finance/CFO 53 -
Director TitleAgeSince
Chairman 72 17/12/2010
Director/Board Member 76 01/03/2009
Director/Board Member 52 01/03/2010
Date Insider Type Main position Quantity % Market Cap.
25/25/25Buy

Chief Executive Officer

632 0.0013%
25/25/25Buy

Chief Executive Officer

15,000 0.0319%
25/25/25Buy

Chief Executive Officer

6,748 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
-2.94%-2.38%-35.98%-26.21% 31Cr
-2.48%+8.83%+54.68%+158.23% 1,09700Cr
-1.76%+9.81%+66.64%+54.77% 62TCr
-1.05%+9.40%+38.03%+88.88% 45TCr
-1.62%+6.34%+29.51%+24.01% 33TCr
-1.38%+6.09%+37.91%+25.49% 29TCr
+0.30%+5.24%+31.61%+42.02% 29TCr
-0.10%+4.88%-28.09%-41.02% 21TCr
+0.44%+5.05%+30.67%+63.74% 19TCr
+0.01%+1.18%+14.16%+66.21% 16TCr
Average -0.97%+6.14%+23.91%+45.61% 36.47TCr
Weighted average by Cap. -1.28%+8.72%+41.33%+79.27%

Financials

2024 2025
Net sales 2,20500Cr 142.38Cr 124.62Cr 115.04Cr 107.31Cr 202.19Cr 13TCr 205.81Cr 1.38TCr 535.72Cr 6.64TCr 534.91Cr 522.96Cr 23TCr 2,45100Cr 158.3Cr 138.56Cr 127.91Cr 119.31Cr 224.8Cr 15TCr 228.83Cr 1.53TCr 595.64Cr 7.39TCr 594.74Cr 581.46Cr 26TCr
Net income 2.4TCr 1.55Cr 1.36Cr 1.25Cr 1.17Cr 2.2Cr 146.69Cr 2.24Cr 15Cr 5.84Cr 72Cr 5.83Cr 5.7Cr 252.17Cr -6.95TCr -4.49Cr -3.93Cr -3.63Cr -3.38Cr -6.37Cr -424.42Cr -6.49Cr -44Cr -17Cr -209.43Cr -17Cr -16Cr -729.62Cr
Net Debt 1,04200Cr 67Cr 59Cr 54Cr 51Cr 96Cr 6.36TCr 97Cr 652.16Cr 253.18Cr 3.14TCr 252.8Cr 247.16Cr 11TCr 1,39400Cr 90Cr 79Cr 73Cr 68Cr 127.83Cr 8.51TCr 130.12Cr 872.45Cr 338.71Cr 4.2TCr 338.19Cr 330.64Cr 15TCr
Logo GC Corp.
Green Cross Holdings is a Korea-based holding company principally engaged in the manufacture and distribution of pharmaceuticals. The Company operates its business through five segments. The Pharmaceutical Manufacturing and Sale segment mainly manufactures and sells blood products, general pharmaceuticals, vaccines and over-the-counter (OTC) drugs. The Medical Service and System Development and Supply segment primarily provides healthcare services. The Diagnostic and Analysis segment mainly engages in blood diagnostics and genetic analysis business. The Leasing and Service Business segment is primarily involved in the real estate leasing and the management of affiliated group companies. The Other segment mainly operates livestock operation and other business.
Employees
144
Date Price Change Volume
30/26/30 10,250.00 -2.94% 60,459
29/26/29 ₩10,560.00 +8.53% 1,05,735
26/26/26 ₩9,730.00 -3.28% 1,65,891
25/26/25 ₩10,060.00 -1.57% 1,05,001
24/26/24 ₩10,220.00 +1.79% 1,50,182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. A005250 Stock